Medical/Pharmaceuticals
SD Biosensor Successfully Finishes JP Morgan Healthcare Conference
* Entering the US market in earnest by acquiring Meridian * Expanding into a direct sales system in 10 countries within the year * Launching plans, including the new product, 'STANDARD M10 FAST RT-PCR, CGMS' SEOUL, South Korea, Jan. 13, 2023 /PRNewswire/ -- SD Biosensor, Inc. (KS137310), Sou...
2023-01-13 15:11
3517
DEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
- Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a novel 3-month ext...
2023-01-12 17:00
2230
iNtRON is finalizing the SAL200 Tech Transfer
* Including the contract transfers of the external studies planned for the
successful out-licensing and commercialization of SAL200 BOSTON and SEOUL,
South Korea, Jan. 11, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON",
www.intodeworld.com
2023-01-12 09:34
2984
Meihua International Medical Technologies Co., Ltd. Enters into Strategic Partnership with Getein Biotech Inc. to Jointly Produce and Sell Covid-19 Antigen Test Kits and IVDs
YANGZHOU, China, Jan. 11, 2023 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, today announced the Company's s...
2023-01-11 21:30
4045
Global Times: 'Zhang Wenhong phenomenon' shows inclusiveness of China's public opinion sphere; policymaking based on science helps nation firmly hold strategic initiative of epidemic fight
BEIJING, Jan. 11, 2023 /PRNewswire/ -- On Friday, China released the 10th edition of the COVID-19 prevention and control protocol. Moreover, starting from Sunday, the country downgraded the management of COVID-19 from Class A to Class B and lifted quarantine requirements for inbound travelers. Th...
2023-01-11 17:49
2443
Samsung Biologics receives the Terra Carta Seal in recognition of the company's commitment to creating a sustainable future
* Samsung Biologics is one of 19 companies to have been awarded the 2022 Terra Carta Seal. * The Terra Carta Seal recognises global companies which are driving innovation and demonstrating their commitment to, and momentum towards, the creation of genuinely sustainable markets. * Designed b...
2023-01-11 08:01
3374
Dizal Announces China CDE Acceptance of New Drug Application for Sunvozertinib for Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations
SHANGHAI, Jan. 10, 2023 /PRNewswire/ -- Dizal (SHEX: 688192) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for sunvozertinib for the treatment of advanced NSCLC with EGFR exon20ins...
2023-01-10 17:03
3209
FAPON to attend 41st Annual J.P. Morgan Healthcare Conference
SHENZHEN, China, Jan. 10, 2023 /PRNewswire/ -- FAPON, a leading life sciences company, today announces that its senior executive management will attend the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Jielun ZHU, CFO & CIO of FAPON, will be making a corporate presentation o...
2023-01-10 16:37
3149
SK Biopharmaceuticals to Present Future Plan for Global Investors, Partners at 'SK Bio Night'
SK Inc.'s 1st SK Bio Night on the sidelines of J.P. Morgan Healthcare Conference offers a glimpse into the future of its global business in new drug, CDMO, biotech SK Biopharmaceuticals joins SK Inc.'s Bio Investment Center, SK pharmteco, or 'SK bio family,'for potential investment, partnerships...
2023-01-10 07:00
2792
SK Inc. hosts "SK Bio Night" in San Francisco to expand global partnerships
* SK to spark innovative ideas and identify new business opportunities by presenting its global strategy and growth roadmap to over 50 partners * Newly appointed executives to lead SK's biopharmaceutical businesses to attend the event * SK Inc. to promote the competitiveness of K-bio and pro...
2023-01-10 07:00
2470
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
U.S. now open for enrollment of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Jan. 9, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying tre...
2023-01-09 23:25
3608
FlatTech LLC Receives Innovative Technology Contract from Vizient for EpiFaith(R) Syringe for safer epidurals
Contract awarded for products that bring improvement to health care industry
TAIPEI, Jan. 9, 2023 /PRNewswire/ -- FlatTech LLC announced its EpiFaith®
Syringe for epidural has received an Innovative Technology contract from
Vizient, Inc.
2023-01-09 21:00
3206
SK bioscience's Zoster Vaccine Receives Biologics License Application Approval in Malaysia
* The world-second developed shingles vaccine 'SKYZoster™' is approved by the National Pharmaceutical Regulatory Agency (NPRA) * SK biosciences plans to launch the zoster vaccine with proven efficacy and safety starting in Southeast Asian market SEOUL, South Korea, Jan. 9, 2023 /PRNewswire/ -...
2023-01-09 21:00
3736
Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine
MORRISVILLE, N.C., Jan. 9, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) ap...
2023-01-09 20:00
2603
Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S
BEIJING and SHANGHAI and BOSTON, Jan. 8, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has completedthe first patient dosage of its in-house R&D drug candidate Aurora A Inhibitor JAB-2485 in a Phase I/IIa clinical trial for advanced solid tumour patients in U.S. JAB-2485 is a high...
2023-01-08 14:17
4303
Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US
PRINCETON, N.J., Jan. 7, 2023 /PRNewswire/ -- Fosun Pharma (600196.SH, 02196.HK) has recently entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the commercialisation of Henlius independently developed anti-PD-1 monoclonal antibody (mAb) serplulimab inth...
2023-01-07 17:29
4978
Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD
Hepatic Impairment and Drug-Drug Interaction Study Results Presented PRINCETON, N.J., Jan. 6, 2023 /PRNewswire/ -- KBP Biosciences PTE. Ltd. ("KBP Biosciences" or the "Company"), a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medici...
2023-01-06 21:00
2918
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation)
MELBOURNE, Australia and SAN FRANCISCO, Jan. 6, 2023 /PRNewswire/ -- Alterity Therapeutics Limited ("Alterity" or the "Company") (ASX:ATH, NASDAQ:ATHE), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that its Board of D...
2023-01-06 20:25
4987
Double-blind period completes! Primary endpoint analysis of phase 3 clinical trial to be conducted for China's first hormone replacement treatment targeting hypoparathyroidism
Submission of NDA to the NMPA is planned within 2023 at the earliest SHANGHAI, Jan. 6, 2023 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, announced today that it has completed the double-blind period of PaTHway China Trial, a phase 3...
2023-01-06 18:00
2303
Standigm cited as 'Top 10 Generative AI-based startup based on VC Investment, 2019-2021' in Gartner® report
SEOUL, South Korea, Jan. 5, 2023 /PRNewswire/ -- Standigm
2023-01-05 22:00
2496
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21Southeast Asia's China travel map is widening, Traveloka platform data shows
[Picked up by 263 media titles]
2026-10-05 11:51Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
9326
DayOne Files Registration Statement for Proposed Initial Public Offering
2026-10-06 05:28
8548
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
8416
